Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04679064
Title Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Indications

peritoneum cancer

fallopian tube cancer

ovarian cancer

Therapies

Bevacizumab + Gemcitabine

Dostarlimab-gxly + Niraparib

Pegylated liposomal-doxorubicin

Bevacizumab + Topotecan

Paclitaxel

Topotecan

Bevacizumab + Paclitaxel

Bevacizumab + Pegylated liposomal-doxorubicin

Gemcitabine

Age Groups: senior | adult
Covered Countries ITA


No variant requirements are available.